Week In Review: Everest In-Licenses An ADC From Immunomedics In $835 Million Agreement, A China Record For A Single Asset May 5, 2019
Shanghai News
Everest Medicines II of Shanghai, a company backed by C-Bridge Capital, agreed to pay up to $835 million in upfront and milestone payments for Greater China rights to an Immunomedics antibody-drug ...